(a) Notwithstanding another law to the contrary, a research institution may participate in one (1) or more clinical trials involving ibogaine, whether alone or in participation with a multistate research consortium, as long as all clinical trial activity is conducted in compliance with applicable state and federal law.
(b) Participation in a clinical trial under this section must include compliance with a valid United States food and drug administration investigational new drug (IND) authorization, when such authorization is required by federal law.
(c) A research institution may receive and administer federal, private, or philanthropic funding for purposes of conducting research authorized under this section.